ArticleScience (New York, N.Y.)2021
Model-informed COVID-19 vaccine prioritization strategies by age and serostatus.
Article in Science (New York, N.Y.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04944095 (Serology Testing), which is not on this map. Cited by 390 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Serology Testing (Antibody Levels) With Time Following SARS-CoV-2 (Covid-19) Vaccinations in Residents of Nursing, Extended Care, and Over-55 Communities
Who cites it
390 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Prior infections and effectiveness of SARS-CoV-2 vaccine in test-negative studies: a systematic review and meta-analysis.American journal of epidemiology · 2024Pooled it
- Incorporating Social Determinants of Health in Infectious Disease Models: A Systematic Review of Guidelines.Medical decision making : an international journal of the Society for Medical Decision Making · 2024Pooled it
- Predictive models for health outcomes due to SARS-CoV-2, including the effect of vaccination: a systematic review.Systematic reviews · 2024Pooled it
- Inequality in the distribution of Covid-19 vaccine: a systematic review.International journal for equity in health · 2022Pooled it
- Efficacy versus coverage: population-level impacts of vaccination schemes.Infectious Disease Modelling · 2027Article
- Optimizing vaccine site locations while considering travel inconvenience and public health outcomes.Health care management science · 2026Article
- Epidemiological characteristics and transmission dynamics of COVID-19 outbreaks in China: a four-year retrospective analysis using extended SEIR models.BMC public health · 2026Article
- Beyond influenza-like-illness: data-driven syndromic surveillance for fine-scale monitoring of seasonal respiratory viruses.medRxiv : the preprint server for health sciences · 2026Article
- Modeling individual self-protective behavior during epidemics.PLoS computational biology · 2026Article
- How new approach methods are reshaping virology research.Journal of virology · 2026Review
- Assessing the Impact of Timing and Coverage of United States COVID-19 Vaccination Campaigns: A Multi-Model Approach.medRxiv : the preprint server for health sciences · 2026Article
- A compartmental model of variant coexistence, dynamics and dominance in infectious diseases: Case for SARS-CoV-2 in Abu Dhabi.Infectious Disease Modelling · 2026Article
- Article
- Impact of socio-economic and political factors on global COVID-19 vaccine coverage: an empirical study.Tropical medicine and health · 2026Article
- Optimizing vaccination strategies under uncertainty to prevent epidemics.Frontiers in public health · 2026Article
- Smallpox outbreak scenarios and reactive intervention protocols: A mathematical model-based analysis applied to the Republic of Korea.PloS one · 2026Article
- COVID-19 Infection and Vaccination Among Healthcare Workers in a South African Academic Hospital: Burden, Risk Factors, and Protective Trends.International journal of environmental research and public health · 2025Article
- Social inequalities in vaccine coverage and their effects on epidemic spreading.PLoS computational biology · 2025Article
- Equity considerations in COVID-19 vaccine allocation modelling: a methodological study.Interface focus · 2025Review
- Why population heterogeneity matters for modelling infectious diseases.Interface focus · 2025Article
330 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Update of
Authors and funding
7 authors.
Funding
Abstract
Limited initial supply of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine raises the question of how to prioritize available doses. We used a mathematical model to compare five age-stratified prioritization strategies. A highly effective transmission-blocking vaccine prioritized to adults ages 20 to 49 years minimized cumulative incidence, but mortality and years of life lost were minimized in most scenarios when the vaccine was prioritized to adults greater than 60 years old. Use of individual-level serological tests to redirect doses to seronegative individuals improved the marginal impact of each dose while potentially reducing existing inequities in COVID-19 impact. Although maximum impact prioritization strategies were broadly consistent across countries, transmission rates, vaccination rollout speeds, and estimates of naturally acquired immunity, this framework can be used to compare impacts of prioritization strategies across contexts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.